Novo Nordisk said India’s drug regulator approved Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty liver disease. The approval expands the drug’s label beyond obesity and supports incremental market access in India. While not a company-wide financial update, it’s a meaningful regulatory win that should be supportive for growth expectations.
Novo Nordisk said India’s drug regulator approved Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty liver disease. The approval expands the drug’s label beyond obesity and supports incremental market access in India. While not a company-wide financial update, it’s a meaningful regulatory win that should be supportive for growth expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
